ClinicalTrials.gg
Not yet recruitingNCT07206641Updated Nov 18, 2025

The Effect of Inspiratory Exercises on Diaphragm and Intercostal Muscle Thickness in Stroke Patients

An observational study in Stroke, sponsored by Marmara University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-11-18.

Sponsored by Marmara University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
35
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Stroke by Marmara University — 4 open to participants now, 4 under way, none of them phase 3. Stroke · Marmara University.

Started
2025
the only one that year
Observational
6 of 14
3 open now
Registered
11th of 14
by date

Among the 14 studies in Stroke by Marmara University, this one is the only one that started in 2025, is one of 6 observational ones, and was the 11th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

4 of the 14 studies in Stroke by Marmara University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Stroke by Marmara University, or all of them as a file.
02

Study summary

The aim of this study is to investigate the effect of inspiratory muscle strengthening exercises on bilateral parasternal intercostal muscle thickness and bilateral diaphragm muscle thickness in stroke patients and to present new data on whether the possible effect on the affected side can be associated with changes in respiratory parameters. Furthermore, as previous literature has shown that 4-week exercise programs are more effective than >6-week exercise programs, an interim assessment is planned for the second week of treatment in this study to evaluate shorter-term changes. Four weeks after completion of the exercise program (in the 8th week), patients will be re-evaluated to track potential short-term effects.

Read the detailed description

Respiratory muscles consist of three main groups that control ventilation: primary inspiratory muscles, secondary inspiratory muscles, and expiratory muscles. The primary inspiratory muscle is the diaphragm, a thin dome-shaped muscle located between the thorax and the abdomen. The diaphragm, the most important respiratory muscle, contributes to 60-80% of the ventilation needs of the human body. However, the diaphragm is not the only inspiratory muscle involved in ventilation. When the load on the diaphragm increases, accessory inspiratory muscles such as the parasternal intercostal muscles, external intercostal muscles, scalene muscles, and sternocleidomastoid muscles are recruited to assist inspiration.

Involvement of the diaphragm and other respiratory muscle groups is a common condition after stroke. Due to the loss of central motor control in stroke patients, contralateral diaphragmatic weakness is observed. The thickness of the diaphragm affected by stroke is approximately 50% of that of age- and sex-matched healthy adults, as shown in studies.

After stroke, the decrease in respiratory muscle strength on the hemiplegic side may lead to pulmonary ventilation and diffusion dysfunction, reduced coughing ability, increased incidence of pulmonary complications, and reduced cardiopulmonary endurance and trunk balance control. Respiratory muscle strengthening exercises are used as an effective method in reducing these problems.

Patients diagnosed with stroke who will be followed with inspiratory strengthening exercises will be monitored by comparing the muscle thicknesses of the affected side and the healthy side. After receiving training on inspiratory strengthening exercises to be given to them, patients will regularly perform these exercises at home, and the consistent correct performance of these exercises will be monitored by a researcher through video calls with the participants over the internet.

Intercostal Muscle Thickness Measurement:

Stroke can affect the functions of respiratory muscles, particularly the accessory respiratory muscles (including the intercostal muscles), due to central nervous system damage. This condition may lead to disturbances in the breathing pattern and hypoxia.

Ultrasonography is used as an easily accessible, inexpensive, and rapid assessment method. It allows visualization of muscle contractions and has been shown to reliably evaluate both diaphragm thickness and intercostal muscle thickness. In this study, ultrasonography will be used to examine the structure and function of the intercostal muscles and to measure muscle thickness at the end of inspiration and expiration.

All patients will be placed in the supine position, and as previously demonstrated by De Troyer, A. et al., data will be obtained from the 2nd intercostal space-which is the most stable and distinct space for evaluating parasternal intercostal muscles-2 to 4 cm lateral to the sternum. After an optimal 2D image is obtained, the intercostal muscle will be evaluated and measured at end-inspiration and end-expiration. A high-frequency linear probe of 6-13 MHz, placed vertically on the chest wall with minimal pressure, will be used.

Intercostal muscle contractility can be evaluated by changes in muscle thickness (the intercostal thickness fraction (ICTf) measured using ultrasonography).

ICTf = (end-inspiration intercostal muscle thickness - end-expiration intercostal muscle thickness) / end-expiration intercostal muscle thickness × 100%

Diaphragm Muscle Thickness Measurement:

After stroke, the diaphragm, one of the primary inspiratory muscles, is prone to atrophy due to central nervous system disorders. Atrophy of the diaphragm leads to decreased exercise capacity associated with muscle fatigue. In stroke patients, the structure of the diaphragm may shift, resulting in changes in the extremities. Pinheiro et al. reported that inspiratory muscle strength in stroke patients reached only half of that in healthy individuals, and that this reduction in inspiratory muscle function may cause functional difficulties.

In this study, ultrasonography will be used to examine the structure and function of the diaphragm and to measure muscle thickness at the end of inspiration and expiration.

All patients will be placed in the supine position, and the probe will be placed in the subcostal area between the right midclavicular line and the anterior axillary line, directed toward the head and back to reach the middle and posterior third of the diaphragm. After an optimal 2D image is obtained, the diaphragm will be evaluated and measured at end-inspiration and end-expiration. A low-frequency convex probe of 2-5 MHz will be used during the measurements.

Diaphragm contractility can be evaluated by changes in diaphragm thickness (the diaphragm thickness ratio (TR) or diaphragm thickness fraction (DTf) measured using ultrasonography).

DTf = (end-inspiration diaphragm thickness - end-expiration diaphragm thickness) / end-expiration diaphragm thickness × 100% Data Evaluation and Follow-up

Bilateral Intercostal Muscle Thickness Measurement:

Will be performed using an ultrasound device before treatment, at the 2nd week of treatment, at the end of treatment (4th week), and 4 weeks after the completion of treatment (8th week).

Bilateral Diaphragm Muscle Thickness Measurement:

Will be performed using an ultrasound device before treatment, at the 2nd week of treatment, at the end of treatment (4th week), and 4 weeks after the completion of treatment (8th week).

Pulmonary Function Tests:

Will be measured using spirometry before treatment, at the end of treatment (4th week), and 4 weeks after the completion of treatment (8th week).

Berg Balance Scale:

Will be evaluated before treatment, at the 2nd week of treatment, at the end of treatment (4th week), and 4 weeks after the completion of treatment (8th week).

Tinetti Test:

Will be evaluated before treatment, at the 2nd week of treatment, at the end of treatment (4th week), and 4 weeks after the completion of treatment (8th week).

Stroke-Specific Quality of Life Scale:

Will be evaluated before treatment, at the 2nd week of treatment, at the end of treatment (4th week), and 4 weeks after the completion of treatment (8th week).

03

Conditions studied

  • Stroke

Browse trials for

Keywords

  • Stroke
  • IMT
  • Inspiratory Muscle Training
  • Diapragm Thickness
  • Intercostal muscle thickness
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients aged 18-65 years diagnosed with stroke Sample Size of the Study: 35 Stroke patients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a history of ischemic or hemorrhagic stroke
  • Aged 18-65 years

Exclusion criteria

Exclusion Criteria:

  • Presence of concomitant acute or chronic lung disease
  • History of thoracic or abdominal surgery
  • Presence of another neuromuscular disease
  • Patients with aphasia or impaired cognition
  • Severe heart disease
  • Active cancer
  • (MMSE) score ≤ 24
  • Active smoking
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
35 participants (estimated)
Patient registry
No

Groups and cohorts

  • GROUP 1: Patients diagnosed with stroke who will be followed with inspiratory strengthening exercise
06

What researchers measure

Primary outcomes

  1. Diaphragm muscle thickness

    In this study, ultrasonography will be used to examine the structure and function of the muscle and to measure muscle thickness at the end of inspiration and expiration.

    Time frame: Will be performed using an ultrasound device before treatment, at the 2nd week of treatment, at the end of treatment (4th week), and 4 weeks after the completion of treatment (8th week).

  2. Intercostal muscle thickness

    In this study, ultrasonography will be used to examine the structure and function of the muscle and to measure muscle thickness at the end of inspiration and expiration.

    Time frame: Will be performed using an ultrasound device before treatment, at the 2nd week of treatment, at the end of treatment (4th week), and 4 weeks after the completion of treatment (8th week).

Secondary outcomes

  1. Berg Balance Scale

    Berg balance scale scores range from 0 to 56. The lower your score, the more at risk you are for losing your balance. The higher your score, the better your functional mobility (ability to move effectively and safely).

    Time frame: Will be evaluated before treatment, at the 2nd week of treatment, at the end of treatment (4th week), and 4 weeks after the completion of treatment (8th week).

  2. Tinetti Test

    The Tinetti test has a gait score and a balance score. It uses a 3-point ordinal scale of 0, 1 and 2. Gait is scored over 12 and balance is scored over 16 totalling 28. The lower the score on the Tinetti test, the higher the risk of falling.

    Time frame: Will be evaluated before treatment, at the 2nd week of treatment, at the end of treatment (4th week), and 4 weeks after the completion of treatment (8th week).

  3. Stroke-Specific Quality of Life Scale

    Stroke-Specific Quality of Life Scale (SS-QoL) is used to assess the life expectancy of a stroke survivor. It is specifically designed for individuals who have had a stroke. Both personal and psychosocial effects are assessed collectively. Scores range from 49-245. Higher scores indicate better functioning.

    Time frame: Will be evaluated before treatment, at the 2nd week of treatment, at the end of treatment (4th week), and 4 weeks after the completion of treatment (8th week).

  4. Forced Vital Capacity

    Forced vital capacity (FVC) measures the total amount of air a person can exhale as quickly and forcefully as possible after taking a deep breath. Measured through spirometry, FVC assesses the lungs' ability to hold air and helps distinguish obstructive from restrictive lung disease.

    Time frame: Will be measured using spirometry before treatment, at the end of treatment (4th week), and 4 weeks after the completion of treatment (8th week)

  5. Forced Expiratory Volume

    FEV₁ (forced expiratory volume in 1 second) measures the amount of air a person can forcefully exhale in the first second after taking a deep breath. This value is used to determine the degree of airway obstruction. The FEV₁/FVC ratio is an important parameter in distinguishing obstructive and restrictive lung diseases.

    Time frame: Will be measured using spirometry before treatment, at the end of treatment (4th week), and 4 weeks after the completion of treatment (8th week).

  6. Maximum Inspiratory Pressure

    Maximum inspiratory pressure (MIP) is a measurement that evaluates the strength of the inspiratory muscles. This test measures the negative pressure created when a person breathes in at maximum effort. MIP assesses the strength of respiratory muscles, such as the diaphragm and intercostal muscles, and is used to diagnose conditions characterized by respiratory muscle weakness.

    Time frame: Will be measured using respiratory pressure meter before treatment, at the end of treatment (4th week), and 4 weeks after the completion of treatment (8th week).

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2025; primary completion for Dec 2026, 12 months later.

Of 838 non-industry observational studies under Stroke, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 92. This study's planned 12 months is below that.

Counting every sponsor, half of 900 studies reached it within 40 months; a quarter within 18 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2025
First posted
Oct 3, 2025
StartEst.
Dec 1, 2025
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Nov 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07206641
Lead sponsor
Marmara University
Responsible party
Sponsor
First posted
Oct 3, 2025
Start date
Dec 1, 2025 (estimated)
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Nov 18, 2025

Study contacts

Oguzhan Kasimoglu
Contact
kasimogluoguzhan@gmail.com
+90 5448911835
Ozge Kenis Coskun
Contact
ozgekenis@gmail.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion